Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A number of germline mutations in DNA damage repair genes ( BRCA1, BRCA2, CHEK2, ATM and PALB2) and in DNA mismatch repair genes ( MLH1, MSH2, MSH6 and PMS2) can drive the development of prostate cancer.
|
30730411 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this article is to provide a review of principles of genetic testing in prostate cancer and highlight the significance of clinical genetic testing of BRCA1/2 and other genes (CHEK2, HOXB13, PALB2), including Lynch syndrome genes (MLH1, MSH2, MSH6, and PMS2) in men with metastatic prostate cancer.
|
30681994 |
2019 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No association was found between CHEK2 mutation status and early-diagnosis or PCa-specific survival time.
|
29520813 |
2018 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found monoallelic truncating/functionally deleterious mutations in seven genes, including ATM and CHEK2, which have previously been associated with PrCa predisposition, and five new candidate PrCa associated genes involved in cancer predisposing recessive disorders, namely RAD51C, FANCD2, FANCI, CEP57 and RECQL4.
|
29659569 |
2018 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Evidence for prostate cancer risk was observed for CHEK2 c.1343T>G OR 3.03 (95% CI 1.53 to 6.03, p=0.0006) for African men and CHEK2 c.1312G>T OR 2.21 (95% CI 1.06 to 4.63, p=0.030) for European men.
|
27595995 |
2016 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation.
|
26447757 |
2015 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, we propose that CHK2 is a negative regulator of androgen sensitivity and prostate cancer growth, and that CHK2 signaling is lost during prostate cancer progression to castration resistance.
|
26573794 |
2015 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CHEK2 is a multi-cancer susceptibility gene whose common germline mutations are known to contribute to the risk of developing breast and prostate cancer.
|
24986639 |
2014 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that testing for germline CHEK2 mutations improves the ability to predict the presence of prostate cancer in screened men, however, the clinical utility of incorporating DNA variants in the screening process is marginal.
|
23722471 |
2013 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To establish the contribution of eight founder alleles in three DNA damage repair genes (BRCA1, CHEK2 and NBS1) to prostate cancer in Poland, and to measure the impact of these variants on survival among patients.
|
23149842 |
2013 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Intriguingly, two other CHEK2 mutations (IVS2+1G>A and I157T) and a CHEK2 large genomic deletion (del9-10) have been associated with an elevated risk for prostate cancer.
|
17661168 |
2008 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate whether it plays an important role in the development of prostate cancer (PRCA) in the Ashkenazi Jewish (AJ) population, we sequenced CHEK2 in 75 AJ individuals with prostate, breast, or no cancer (n=25 each).
|
18571837 |
2008 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in CHEK2 have been associated with a range of cancer types but little is known about disease risks conveyed by CHEK2 mutations outside of the context of breast and prostate cancer.
|
17918154 |
2008 |
Prostate carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In addition, heat treatment induced the phosphorylation of Chk2 proteins examined and led to apoptosis in the prostate cancer cells.
|
18507002 |
2008 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Modest effects on prostate cancer risk were observed for both CHEK2 missense and truncating variants.
|
17372254 |
2007 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that the CHEK2 and TP53 mutations can substitute each other in at least 25% (21/84) of prostate cancers and that DNA damage-signaling pathway plays an important role in prostate cancer tumorigenesis.
|
16941491 |
2006 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these results provide evidence that both germline and somatic CHEK2 mutations identified in prostate cancer may contribute to the development of prostate cancer through the reduction of CHEK2 activation in response to DNA damage and/or oncogenic stress.
|
16835864 |
2006 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Germ line mutations in several genes (BRCA1, BRCA2, and CHEK2) whose products are involved in the DNA damage-signaling pathway have been implicated in prostate cancer risk.
|
17079449 |
2006 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A large deletion of exons 9 and 10 of CHEK2 confers an increased risk of prostate cancer in Polish men.
|
17085682 |
2006 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The relatives of bilateral cases who were wild-type for CHEK2 had three times the population risk of female breast cancer (145 cases: SIR 3.48 (95% CI 2.96-4.09), twice the risk of prostate cancer (34 cases: SIR 2.41, 1.67-3.36) and a large excess of male breast cancer (five cases: SIR 15.06, 4.92-35.36).
|
16257342 |
2005 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A single founder allele of the CHEK2 gene has been associated with predisposition to breast and prostate cancer in North America and Europe.
|
15492928 |
2004 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The risk of prostate cancer is known to be elevated in carriers of germline mutations in BRCA2, and possibly also in carriers of BRCA1 and CHEK2 mutations.
|
15280931 |
2004 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results provide evidence that the two truncating mutations of CHEK2 confer a moderate risk of prostate cancer in Polish men and that the missense change appears to confer a modest risk.
|
15087378 |
2004 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overall, our data suggest that mutations in CHEK2 may contribute to prostate cancer risk and that the DNA-damage-signaling pathway may play an important role in the development of prostate cancer.
|
12533788 |
2003 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results suggest that CHEK2 variants are low-penetrance prostate cancer predisposition alleles that contribute significantly to familial clustering of prostate cancer at the population level.
|
14612911 |
2003 |